CB1 receptor-deficient mice as a model for depression

Neuroscience

Volumn 204, Issue , 2012, Pages 193-206

  Valverde, O ^a   Torrens, M ^b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

CB1 receptors; Depression; Endocannabinoids; Knockout mice; Monoamines; Neurotrophic factors

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

BEHAVIOR CHANGE; BRAIN REGION; CANNABINOID RECEPTOR TYPE 1 GENE; DISEASE ASSOCIATION; DRUG MECHANISM; EMOTIONALITY; EXPERIMENTAL MODEL; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KNOCKOUT MOUSE; MAJOR DEPRESSION; MOOD CHANGE; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR GENE; REVIEW; SEROTONINERGIC SYSTEM;

ANIMALS; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MICE, KNOCKOUT; PITUITARY-ADRENAL SYSTEM; RECEPTOR, CANNABINOID, CB1;

EID: 84857128654     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.09.031     Document Type: Review

References (136)

1. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002, 68:247-286.
2. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC.
3. Anacker C., Zunszain P.A., Carvalho L.A., Pariante C.M. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology 2011, 36:415-425.
4. Anacker C., Zunszain P.A., Cattaneo A., Carvalho L.A., Garabedian M.J., Thuret S., Price J., Pariante C.M. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 2011, 16:738-750.
5. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999, 160:1-12.
6. Aso E., Ozaita A., Valdizán E.M., Ledent C., Pazos A., Maldonado R., Valverde O. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008, 105:565-572.
7. Aso E., Renoir T., Mengod G., Ledent C., Hamon M., Maldonado R., Lanfumey L., Valverde O. Lack of CB1 receptor activity impairs serotonergic negative feedback. J Neurochem 2009, 109:935-944.
8. Bambico F.R., Duranti A., Tontini A., Tarzia G., Gobbi G. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm 2009, 15:1623-1646.
9. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27:11700-11711.
10. Barna I., Zelena D., Arszovszki A.C., Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004, 75:2959-2970.
11. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
12. Barrero F.J., Ampuero I., Morales B., Vives F., de Dios Luna Del Castillo J., Hoenicka J., Garcia-Yebenes J. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics 2005, 5:135-141.
13. Bergamaschi M.M., Queiroz R.H., Chagas M.H., de Oliveira D.C., De Martinis B.S., Kapczinski F., Quevedo J., Roesler R., Schröder N., Nardi A.E., Martín-Santos R., Hallak J.E., Zuardi A.W., Crippa J.A. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011, 36:1219-1226.
14. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
15. Best A.R., Regehr W.G. Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J Neurosci 2008, 28:6508-6515.
16. Beyer C.E., Dwyer J.M., Piesla M.J., Platt B.J., Shen R., Rahman Z., Chan K., Manners M.T., Samad T.A., Kennedy J.D., Bingham B., Whiteside G.T. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010, 39:148-155.
17. Bilkei-Gorzo A., Racz I., Valverde O., Otto M., Michel K., Sastre M., Zimmer A. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc Natl Acad Sci U S A 2005, 102:15670-15685.
18. Blier P., Szabo S.T. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005, 66(Suppl 8):30-40.
19. Boothman L., Raley J., Denk F., Hirani E., Sharp T. In vivo evidence that 5 HT, p 2Creceptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol 2006, 149:861-869.
20. Boothman L.J., Allers K.A., Rasmussen K., Sharp T. Evidence that central 5-HT2A and 5-HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Br J Pharmacol 2003, 139:998-1004.
21. Bremner J.D. Traumatic stress: effects on the brain. Dialogues Clin Neurosci 2006, 8:445-461.
22. Bridges D., Ahmad K., Rice A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001, 133:586-594.
23. Castañé A., Célérier E., Martín M., Ledent C., Parmentier M., Maldonado R., Valverde O. Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology 2006, 50:111-122.
24. Celada P., Puig M., Amargós-Bosch M., Adell A., Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004, 29:252-265.
25. Charney D.S. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry 2004, 161:195-216.
26. Collins P.Y., Patel V., Joestl S.S. Grand challenges in global mental health. Nature 2011, 475:27-30.
27. Conti A.C., Cryan J.F., Dalvi A., Lucki I., Blendy J.A. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002, 22:3262-3268.
28. Costa B., Colleoni M., Conti S., Trovato A.E., Bianchi M., Sotgiu M.L., Giagnoni G. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 2004, 141:4-8.
29. Costanzi M., Cannas S., Saraulli D., Rossi-Arnaud C., Cestari V. Extinction after retrieval: effects on the associative and nonassociative components of remote contextual fear memory. Learn Mem 2011, 18:508-518.
30. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2008, 20(Suppl 1):35-38.
31. Cota D., Steiner M.A., Marsicano G., Cervino C., Herman J.P., Grübler Y., Stalla J., Pasquali R., Lutz B., Stalla G.K., Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2007, 148:1574-1581.
32. Deussing J.M. Animal models of depression. Drug Discov Today 2006, 3:375-383.
33. Di S., Malcher-Lopes R., Halmos K.C., Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 2003, 23:4850-4857.
34. Domschke K., Dannlowski U., Ohrmann P., Lawford B., Bauer J., Kugel H., Heindel W., Young R., Morris P., Arolt V., Deckert J., Suslow T., Baune B.T. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008, 10:751-759.
35. Dremencov E., Weizmann Y., Kinor N., Gispan-Herman I., Yadid G. Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: a role in the antidepressant response. Curr Drug Targets 2006, 7:165-175.
36. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Greer P.J., Mathis C. Serotonin type-1A receptor imaging in depression. Nucl Med Biol 2000, 27:499-507.
37. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
38. Egashira N., Mishima K., Iwasaki K., Fujiwara M. Intracerebral microinjections of delta 9-tetrahydrocannabinol: search for the impairment of spatial memory in the eight-arm radial maze in rats. Brain Res 2002, 952:239-245.
39. File S.E. The benzodiazepine receptor and its role in anxiety. Br J Psychiatry 1988, 152:599-600.
40. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001, 92:91-100.
41. García-Gutiérrez M.S., Manzanares J. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol 2011, 25:111-120.
42. Gibbons R.D., Mann J.J. Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?. Drug Saf 2011, 34:375-395.
43. Givalois L., Naert G., Rage F., Ixart G., Arancibia S., Tapia-Arancibia L. A single brain-derived neurotrophic factor injection modifies hypothalamo-pituitary-adrenocortical axis activity in adult male rats. Mol Cell Neurosci 2004, 27:280-295.
44. Gould T.D., Picchini A.M., Einat H., Manji H.K. Targeting glycogen synthase kinase 3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 2006, 7:1399-1409.
45. Gruber S.A., Rogowska J., Yurgelun-Todd D.A. Altered affective response in marijuana smokers: an FMRI study. Drug Alcohol Depend 2009, 105:139-153.
46. Hajós M., Hajós-Korcsok E., Sharp T. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 1999, 126:1741-1750.
47. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic andpharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16:1395-1398.
48. Hansson A.C., Cintra A., Belluardo N., Sommer W., Bhatnagar M., Bader M., Ganten D., Fuxe K. Gluco- and mineralocorticoid receptor-mediated regulation of neurotrophic factor gene expression in the dorsal hippocampus and the neocortex of the rat. Eur J Neurosci 2000, 12:2918-2934.
49. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
50. Heifets B.D., Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009, 71:283-306.
51. Heisler L.K., Pronchuk N., Nonogaki K., Zhou L., Raber J., Tung L., Yeo G.S., O'Rahilly S., Colmers W.F., Elmquist J.K., Tecott L.H. Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J Neurosci 2007, 27:6956-6964.
52. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
53. Herman J.O., Cullinan W.E. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997, 20:78-84.
54. Hervera A., Negrete R., Leánez S., Martín-Campos J., Pol O. The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neurophatic pain in mice. J Pharmacol Exp Ther 2010, 334:887-896.
55. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 2009, 8:451-458.
56. Hill M.N., Miller G.E., Ho W.S., Gorzalka B.B., Hillard C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41:48-53.
57. Hill M.N., Patel S., Campolongo P., Tasker J.G., Wotjak C.T., Bains J.S. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 2010, 30:14980-14986.
58. Holmes A., Murphy D.L., Crawley J.N. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol Psychiatry 2003, 15(54):953-959.
59. Howlett A.C. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995, 35:607-634.
60. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001, 24:677-736.
61. Hungund B.L., Vinod K.Y., Kassir S.A., Basavarajappa B.S., Yalamanchili R., Cooper T.B., Mann J.J., Arango V. Upregulation of CB 1 receptors and agonist-stimulated [35 S]GTP γ S binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004, 9:184-190.
62. Jacobsen J.P., Mørk A. Chronic corticosterone decreases brain-derived neurotrophic factor (BDNF) mRNA and protein in the hippocampus, but not in the frontal cortex, of the rat. Brain Res 2006, 1110:221-225.
63. Jin K., Xie L., Kim S.H., Parmentier-Batteur S., Sun Y., Mao X.O., Childs J., Greenberg D.A. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 2004, 66:204-208.
64. Jung K.M., Mangieri R., Stapleton C., Kim J., Fegley D., Wallace M., Mackie K., Piomelli D. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 2005, 68:1196-1202.
65. Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000, 10:381-391.
66. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., Freund T.F. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 2001, 21:9506-9518.
67. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
68. Kinsey S.G., Long J.Z., Cravatt B.F., Lichtman A.H. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 2010, 11:1420-1428.
69. Koenigs M., Grafman J. Posttraumatic stress disorder: the role of medial prefrontal cortex and amygdala. Neuroscientist 2009, 15:540-548.
70. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., Weis S. Expression of CB 1 cannabinoid receptor in the anterior cingulated cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007, 114:1055-1063.
71. Lanfumey L., Mannoury La Cour C., Froger N., Hamon M. 5-HT-HPA interactions in two models of transgenic mice relevant to major depression. Neurochem Res 2000, 25:1199-1206.
72. Le Poul E., Boni C., Hanoun N., Laporte A.M., Laaris N., Chauveau J., Hamon M., Lanfumey L. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 2000, 39:110-122.
73. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Böhme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
74. Lesch K.P., Mayer S., Disselkamp-Tietze J., Hoh A., Wiesmann M., Osterheider M., Schulte H.M. 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 1990, 28:620-628.
75. Levinson D.F. The genetics of depression: a review. Biol Psychiatry 2006, 60:84-92.
76. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacol Berl 1995, 119:282-290.
77. Maccarrone M., Valverde O., Barbaccia M.L., Castañé A., Maldonado R., Ledent C., Parmentier M., Finazzi-Agrò A. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci 2002, 15:1178-1186.
78. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacologist 2005, 299-325.
79. Madroñal N, Gruart A, Valverde O, Espadas I, Moratalla I, Delgado-García JM (in press) Involvement of cannabinoid CB1 receptor in associative learning and in hippocampal CA3-CA1 synaptic plasticity. Cereb Cortex. doi:10.1093/cercor/bhr103.
80. Maldonado R., Valverde O., Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006, 29:225-232.
81. Malone D.A., Dougherty D.D., Rezai A.R., Carpenter L.L., Friehs G.M., Eskandar E.N., Rauch S.L., Rasmussen S.A., Machado A.G., Kubu C.S., Tyrka A.R., Price L.H., Stypulkowski P.H., Giftakis J.E., Rise M.T., Malloy P.F., Salloway S.P., Greenberg B.D. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009, 15(65):267-275.
82. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001, 35:5-49.
83. Mann J.J., Currier D.M. Stress, genetics and epigenetic effects on the neurobiology of suicidal behavior and depression. Eur Psychiatry 2010, 25:268-271.
84. Marmigère F., Givalois L., Rage F., Arancibia S., Tapia-Arancibia L. Rapid induction of BDNF expression in the hippocampus during immobilization stress challenge in adult rats. Hippocampus 2003, 13:646-655.
85. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutiérrez S.O., van der Stelt M., López-Rodriguez M.L., Casanova E., Schütz G., Zieglgänsberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
86. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., Di M V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
87. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002, 159:379-387.
88. Mato S., Aso E., Castro E., Martín M., Valverde O., Maldonado R., Pazos A. CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J Neurochem 2007, 103:2111-2120.
89. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
90. Melis M., Perra S., Muntoni A.L., Pillolla G., Lutz B., Marsicano G., Di Marzo V., Gessa G.L., Pistis M. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 2004, 24:10707-10715.
91. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
92. Mitchell P.B., Morris M.J. Depression and anxiety with rimonabant. Lancet 2007, 370:1671-1672.
93. Monteleone P., Bifulco M., Maina G., Tortorella A., Gazzerro P., Proto M.C., Di Filippo C., Monteleone F., Canestrelli B., Buonerba G., Bogetto F., Maj M. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 2010, 61:400-404.
94. Moreira F.A., Crippa J.A. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009, 31:145-153.
95. Murphy D., Costall B., Smythe J.W. Regulation of hippocampal theta activity by corticosterone: opposing functions of mineralocorticoid and glucocorticoid receptors. Brain Res Bull 1998, 45:631-635.
96. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436-1442.
97. Murrough JW, Huang Y, Hu J, Henry S, Williams W, Gallezot JD, Bailey CR, Krystal JH, Carson RE, Neumeister A (in press) Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. Biol Psychiatry. doi: 10.1016/j.biopsych. 2011.07.003, in press.
98. Murrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV (in press) Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. doi:10.1016/j.nlm.2011.06.006.
99. Najt P., Fusar-Poli P., Brambilla P. Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res 2011, 186:159-164.
100. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006, 59:1151-1159.
101. Owen J.R., Nemeroff C.B. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998, 7(Suppl 1):24-32.
102. Pamplona F.A., Takahashi R.N. WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci Lett 2006, 397:88-92.
103. Parrish J.C., Nichols D.E. Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase C-dependent mechanism. J Neurochem 2006, 99:1164-1175.
104. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145:5431-5438.
105. Radley J.J., Morrison J.H. Repeated stress and structural plasticity in the brain. Ageing Res Rev 2005, 4:271-287.
106. Ravindran L.N., Stein M.B. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010, 71:839-854.
107. Reibaud M., Obinu M.C., Ledent C., Parmentier M., Böhme G.A., Imperato A. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 1999, 379:R1-R2.
108. Riegel A.C., Lupica C.R. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 2004, 24:11070-11078.
109. Robbe D., Kopf M., Remaury A., Bockaert J., Manzoni O.J. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A 2002, 99:8384-8388.
110. Sanchis-Segura C., Cline B.H., Marsicano G., Lutz B., Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacol Berl 2004, 176:223-232.
111. Sapolsky R.M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000, 48:755-765.
112. Sharp T., Boothman L., Raley J., Quérée P. Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 2007, 28:629-636.
113. Smith D.F., Jakobsen S. Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol 2009, 19:611-628.
114. Steiner H., Bonner T.I., Zimmer A.M., Kitai S.T., Zimmer A. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci U S A 1999, 96:5786-5790.
115. Steiner M.A., Wanisch K., Monory K., Marsicano G., Borroni E., Bächli H., Holsboer F., Lutz B., Wotjak C.T. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 2008, 8:196-208.
116. Suenaga T., Kaku M., Ichitani Y. Effects of intrahippocampal cannabinoid receptor agonist and antagonist on radial maze and T-maze delayed alternation performance in rats. Pharmacol Biochem Behav 2008, 91:91-96.
117. Szabo B., Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol 2005, 168:327-365.
118. Tzavara E.T., Wade M., Nomikos G.G. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 2003, 23:9374-9384.
119. Urbanski M.J., Kovacs F.E., Szabo B. Endocannabinoid-mediated synaptically evoked suppression of GABAergic transmission in the cerebellar cortex. Neuroscience 2010, 169:1268-1278.
120. Urigüen L., Fernández B., Romero E.M., De Pedro N., Delgado M.J., Guaza C., Schmidhammer H., Viveros M.P. Effects of 14-methoxymetopon, a potent opioide agonist, on the responses to the tail electric stimulation test and plus-maze activity in male rats: neuroendocrine correlates. Brain Res Bull 2002, 57:661-666.
121. Urigüen L., Pérez-Rial S., Ledent C., Palomo T., Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 2004, 46:966-973.
122. Valverde O. Participation of the cannabinoid system in the regulation of emotional-like behaviour. Curr Pharm Des 2005, 11:3421-3429.
123. Valverde O., Karsak M., Zimmer A. Análisis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handbook Exp Pharmacologist 2005, 168:117-145.
124. Varvel S.A., Lichtman A.H. Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 2002, 301:915-924.
125. Vinod K.Y., Arango V., Xie S., Kassir S.A., Mann J.J., Cooper T.B., Hungund B.L. Elevated levels of endocannabinoids and CB 1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 2005, 57:480-486.
126. Vinod K.Y., Kassir S.A., Hungund B.L., Cooper T.B., Mann J.J., Arango V. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatr Res 2010, 44:591-597.
127. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16:239-249.
128. Watanabe Y., Gould E., McEwen B.S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res 1992, 588341-588345.
129. Wenger T., Jamali K.A., Juanéda C., Léonardelli J., Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun 1997, 237:724-728.
130. Wilson N., Cadet J.L. Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. J Addict Dis 2009, 28:309-319.
131. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
132. Wise L.E., Iredale P.A., Lichtman A.H. The cannabinoid CB(1) receptor antagonist CE prolongs spatial memory duration in a rat delayed radial arm maze memory task. Eur J Pharmacol 2008, 590:246-249.
133. Witkins J.M., Tzavara E., Davis R.J., Li X., Nomikos G.G. A therapeuthic role for cannabinoid CB1 receptor antagonist in major depressive disorders. Trends Pharmacol Sci 2005, 26:609-617.
134. Yu X.H., Cao C.Q., Martino G., Puma C., Morinville A., St.-Onge S., Lessard E., Perkins M.N., Laird J.M. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 2010, 151:337-344.
135. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003, 17:2750-2754.
136. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999, 96:5780-5785.